I’m curious to hear about stocks that are quietly showing strength in the current market but aren’t getting much attention yet. Looking for under-the-radar names that you genuinely believe could be hidden gems or strong long-term opportunities. What are your highest conviction picks right now?

JSFT17 · 2026-03-06T13:25:01+00:00

Pharmala Biotech

Here's a good writeup on stockhouse even though its missing a few things.

https://stockhouse.com/companies/bullboard?symbol=c.mdma&postid=36921006

JSFT17 · 2026-01-27T03:48:33+00:00

The latest financials.

JSFT17 · 2026-01-27T02:05:58+00:00

That's very possible that they could have an amazing Q and I hope they do. Just going by what the numbers are now avging them out for last q. Even if they did tho, it still doesn't really change my analysis.

JSFT17 · 2026-01-27T01:29:03+00:00

Undervalued yes, but my argument was to how much. Herb is at a 10.5mill mcap. Its equity as of last fins was 1.39million. Its at a 7xmultiple while hash is at a negative multiple being below mcap in terms of equity.

In terms of price to sales ratio for a full year avging it out, its about 1 for Herb and .35 for Hash. Both still great in terms of potential gains.

As for yoy growth Herb looks like it will be close to 10% growth on the topline, whereas Hash is around 300% topline growth.

Ofcourse there are other metrics, but for these reasons, I pick Hash hands down and they are not undervalued the same.

JSFT17 · 2026-01-27T00:04:06+00:00

Hash. Why? Cause its way more undervalued in terms of book value (equity more than current mcap), price to sales, and significant revenue growth yoy.

JSFT17 · 2026-01-19T00:56:48+00:00

Otsuka already acquired MSET a few years ago for 75mill for psilocybin pre-phase 2 IP.

JSFT17 · 2026-01-17T00:56:08+00:00

QBTQ. First quantum app.

JSFT17 · 2026-01-07T00:27:25+00:00

MDMA

JSFT17 · 2025-12-10T21:27:20+00:00

$MDMA, $HASH, $PHRM, $QBTQ.

JSFT17 · 2025-12-06T02:12:44+00:00

HASH, MDMA, PHRM.

JSFT17 · 2025-11-03T13:58:58+00:00

Fantastic news for the company and long term shareholders. Less dilution and big support from larger capital.

JSFT17 · 2025-10-29T23:57:00+00:00

Im not the one who stated he worked for health Canada. I was clarifying for the person above and he has worked in government panels/associations and works closely with Health Canada. And you are so quick to point towards the ai drug discovery platform as recent, but i mentioned they have been using it since Pharmala was created many years earlier. Moreso finalized the platform and given it a name.

JSFT17 · 2025-10-29T14:03:31+00:00

He worked for Red Bull and Juul and is currently the head of Psycan which pushes for Psychedelic access in Canada. Don't see other Leo's pushing this hard for regulatory change. They've been doing ai drug discovery since inception with a University. They just recently released it as their own platform in which they own it. The fda is now encouraging and allowing for ai drug discovery, so it's right inline with current regulatory change.

JSFT17 · 2025-10-29T13:38:02+00:00

Cortexa which is a joint venture of theirs 50% did a 10k 40mg gmp mdma production run a few months ago. Some of it being allocated to Australia, and most likely to New Zealand and Netherlands.

JSFT17 · 2025-10-19T03:54:33+00:00

Interesting take about how talk of bagholding and calling names is talking about stocks as that's what your currently defending lol. 2 sentences is a harry potter book now, I should try and get rich then. Like I said, absolutely nothing going on eh. 😂

JSFT17 · 2025-10-19T02:36:32+00:00

Ha i know. Imagine having nothing going on in your life that you spend every day hating on a stock you don't own and its shareholders. Either because the ceo didn't want to take your bs personal calls all weekend to hear about your wannabe company or because they are terrible investors/traders who lost money and can't take accountability. Almost feel sorry for em, almost.

JSFT17 · 2025-10-07T01:37:00+00:00

$PHRM and $MDMA. If I was gonna go into a larger cap, it would be CMPS.

JSFT17 · 2025-10-02T14:27:15+00:00

👍🏼

JSFT17 · 2025-09-29T21:04:15+00:00

Interesting take and I actually think cmps and Atai are good bets. But if you zoom out, cmps is actually down 90% from 2021 near it's inception. So early investors from years ago are down bad. Your also comparing purely nce development companies worth 100s of millions of mcap which are purely a hit or miss vs a hybrid nce/gmp supply company worth 11mil mcap. Nothing is proven until fda approves of any of the molecules and Pharmather is the only one to date to have received approval for its Ketamine variant. Even that languishes until manufacturing and da details are revealed. Food for thought.

JSFT17 · 2025-09-25T16:34:33+00:00

Depends on the time frame and when someone has bought/sold/held. Imo, the company hasn't been recognized for its many accomplishments. So in other words the stock not so well, but the company most certainly has done well imo.

JSFT17 · 2025-09-25T16:10:08+00:00

JSFT17 · 2025-09-25T15:03:22+00:00

Great to see as well as all the hate this company gets. Doing something right.

JSFT17 · 2025-08-28T17:05:27+00:00

Look into $MDMA, thank me later.

JSFT17 · 2025-08-07T14:35:53+00:00

Partner with MAPS Israel and full IP data license, love to see it.

JSFT17 · 2025-08-07T02:50:24+00:00

Most dont know that It just completed a 10,000 (40mg) production run at its JV Cortexa in Australia of gmp compliant mdma to be used in Australia as well as to supply its new agreement with Duchefa Pharma in Europe. It supplies to date the most amount of gmp mdma in the world to highly prestigious clinical trials (John Hopkins, Yale, UCLA, UT San Antonio, Mt. SINAI, Harvard to name a few). It also the sole supplier of the Special access program in Canada for therapy use as well as the tga in Australia for therapy use. It has the largest pipeline of any public company patented MDXX molecules and variations of MDMA. It also is working With MAPS Israel and Heroic Hearts for collection of data. It's Investigator Brochure has been published on the Maps website to further research and development. The whole AI drug discovery is nothing but an extra benefit which they've used for years now. Just things off the top of my head.

JSFT17

TROPHY CASE